ArticleSignal transduction and targeted therapy2024

First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.

Xiaofeng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.